2. Search Result
Search Result
Results for "

b0101

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0101
    Fluconazole
    20+ Cited Publications

    UK-49858

    		 Environmental Pollutants Antibiotic Fungal Bacterial Infection Cancer
    Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC99s range from 0.20 μg/mL to 0.39 μg/mL .
    Fluconazole
  • HY-B0101S
    Fluconazole-d4

    UK-49858-d4

    		 Isotope-Labeled Compounds Fungal Antibiotic Infection
    Fluconazole-d4 is the deuterium labeled Fluconazole. Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC99s range from 0.20 μg/mL to 0.39 μg/mL .
    Fluconazole-d4
  • HY-B0101R
    Fluconazole (Standard)

    UK-49858 (Standard)

    		 Reference Standards Fungal Antibiotic Bacterial Infection Cancer
    Fluconazole (Standard) is the analytical standard of Fluconazole. This product is intended for research and analytical applications. Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC99s range from 0.20 μg/mL to 0.39 μg/mL .
    Fluconazole (Standard)
  • HY-B0101S1
    Fluconazole-13C2,15N

    UK-49858-13C2,15N

    		 Isotope-Labeled Compounds Fungal Antibiotic Bacterial Infection Cancer
    Fluconazole-13C2,15N (UK-49858-13C2,15N) is the 13C and 15N labeled isotope of Fluconazole (HY-B0101). Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC99s range from 0.20 μg/mL to 0.39 μg/mL .
    Fluconazole-13C2,15N
  • HY-B0101B
    Fluconazole mesylate

    UK 49858 mesylate

    		 Fungal Antibiotic Bacterial Infection Cancer
    Fluconazole (mesylate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.
    Fluconazole mesylate
  • HY-B0101A
    Fluconazole hydrate

    UK 49858 hydrate

    		 Fungal Antibiotic Bacterial Infection Cancer
    Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.
    Fluconazole hydrate
  • HY-B2153
    Tetraethylenepentamine pentahydrochloride

    		Cuproptosis Bacterial Infection
    Tetraethylenepentamine pentahydrochloride is an orally active copper chelator and copper mobilizer. Tetraethylenepentamine pentahydrochloride exhibits growth inhibitory and hypolipidemic properties. Tetraethylenepentamine pentahydrochloride significantly increases urinary copper excretion and reduces renal copper accumulation in copper overload models, but does not significantly alter hepatic copper levels. Tetraethylenepentamine pentahydrochloride exerts growth inhibitory effects on Candida albicans and Fluconazole (HY-B0101)-resistant strains, and can be widely used in studies related to Wilson's disease and Candida infections .
    Tetraethylenepentamine pentahydrochloride
  • HY-156090
    PK-10

    		Mitochondrial Metabolism Fungal Infection
    PK-10 is a synergistic antibacterial agent of Fluconazole (HY-B0101) and has strong antifungal activity against a variety of Fluconazole-resistant Candida albicans strains. PK-10 combined with Fluconazole can inhibit hyphae formation and induce the accumulation of reactive oxygen species. It further causes damage to mitochondrial membrane potential, reduces intracellular ATP content, and leads to mitochondrial dysfunction .
    PK-10
  • HY-173490
    Antifungal agent 131

    		Fungal Infection
    Antifungal agent 131 (compound A20) is an antifungal compound with a minimum inhibitory concentration (MIC) of 64 μg/mL. Antifungal agent 131 demonstrates excellent antifungal potential when used in combination with Fluconazole (HY-B0101) .
    Antifungal agent 131
  • HY-162271
    Antibacterial agent 187

    		Topoisomerase Fungal Infection
    Antibacterial agent 187 (IKE7) is a derivative containing imidazole and triazolacridone structures that target yeast topoisomerase II. Antibacterial agent 187 has antifungal activity and MIC value of resistance to fluconazole (HY-B0101) is 32-64 μg/mL .
    Antibacterial agent 187
  • HY-136764
    CYP51-IN-14

    		Fungal Infection
    CYP51-IN-2 (compound 1n), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 1 μg/mL for Microsporum gypseum and Candida albicans .
    CYP51-IN-14
  • HY-136759
    CYP51-IN-9

    		Fungal Infection
    CYP51-IN-2 (compound 1i), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 62.5 for Microsporum gypseum and Candida albicans .
    CYP51-IN-9
  • HY-136762
    CYP51-IN-12

    		Fungal Infection
    CYP51-IN-2 (compound 1l), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans .
    CYP51-IN-12
  • HY-136754
    CYP51-IN-4

    		Fungal Infection
    CYP51-IN-2 (compound 1d), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans .
    CYP51-IN-4
  • HY-136763
    CYP51-IN-13

    		Fungal Infection
    CYP51-IN-2 (compound 1m), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-13
  • HY-173206
    Antifungal agent 128

    		Fungal Infection
    Antifungal agent 128 (Compound 3ja) is an antifungal agent. When used in combination with Fluconazole (HY-B0101), the MIC range against C. albicans strains is 0.5-4 μg/mL. Antifungal agent 128 can be used in the research of the anti-infection field .
    Antifungal agent 128
  • HY-136758
    CYP51-IN-8

    		Fungal Infection
    CYP51-IN-2 (compound 1h), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 15.6 and 62.5 ng/mL for Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-8
  • HY-153620
    Antifungal agent 55

    		Fungal Infection
    Antifungal agent 55 (compound A07) is a potent antifungal agent, against Fluconazole (HY-B0101)-resistant strains. Antifungal agent 55 is more effective than Miconazole (HY-B0454). Antifungal agent 55 inhibits Candida albicans strains with MIC values of 0.25-1 μg/mL .
    Antifungal agent 55
  • HY-116686
    Inz-1

    		Cytochrome P450 Fungal Infection
    Inz-1 is a potent and selective mitochondrial cytochrome bc1 inhibitor for yeast (IC50=8.092 μM) over humans (IC50=45.320 μM). Inz-1 reverses Fluconazole (HY-B0101) or other triazole antifungals’ resistance in the pathogenic fungus Candida albicans .
    Inz-1
  • HY-113611
    SDZ89-485

    		Fungal Infection
    SDZ89-485 is an orally active triazole antifungal agent. The peak concentration of SDZ89-485 is lower, but it exhibits a stronger anti-sporofungus effect in the mouse model than Fluconazole (HY-B0101) with a higher peak concentration. SDZ89-485 can be used in studies on anti-sporofungus .
    SDZ89-485
  • HY-153622
    Antifungal agent 57

    		Fungal Infection
    Antifungal agent 57 (compound A19) is a potent antifungal agent, against Fluconazole (HY-B0101)-resistant strains. Antifungal agent 57 is more effective than Miconazole (HY-B0454). Antifungal agent 57 inhibits Candida albicans strains with MIC values of 0.5-2 μg/mL .
    Antifungal agent 57
  • HY-153623
    Antifungal agent 58

    		Fungal Infection
    Antifungal agent 58 (compound A21) is a potent antifungal agent, against Fluconazole (HY-B0101)-resistant strains. Antifungal agent 58 is more effective than Miconazole (HY-B0454). Antifungal agent 58 inhibits Candida albicans strains with MIC values of 0.06-8 μg/mL .
    Antifungal agent 58
  • HY-153619
    Antifungal agent 54

    		Fungal Infection
    Antifungal agent 54 (compound A05) is a potent antifungal agent, against Fluconazole (HY-B0101)-resistant strains. Antifungal agent 54 is more effective than Miconazole (HY-B0454). Antifungal agent 54 inhibits Candida albicans strains with MIC values of 0.25-1 μg/mL .
    Antifungal agent 54
  • HY-153621
    Antifungal agent 56

    		Fungal Infection
    Antifungal agent 56 (compound A09) is a potent antifungal agent, against Fluconazole (HY-B0101)-resistant strains. Antifungal agent 56 is more effective than Miconazole (HY-B0454). Antifungal agent 56 inhibits Candida albicans strains with MIC values of 0.03-0.25 μg/mL .
    Antifungal agent 56
  • HY-120432
    CaMdr1p-IN-1

    		Fungal ATP-binding cassette (ABC) transporters Infection
    CaMdr1p-IN-1 (Compound A) is an inhibitor for the major facilitator superfamily transporter CaMdr1p. CaMdr1p-IN-1 exhibits chemosensitizing efficacy. CaMdr1p-IN-1 synergizes with Fluconazole (HY-B0101), that inhibits CaMdr1p overexpressing Candida albicans with MIC of 10 μM .
    CaMdr1p-IN-1
  • HY-155198
    Antifungal agent 72

    		Fungal Infection
    Antifungal agent 72 (Compound B8) is a potent antifungal agent. Antifungal agent 72 suppresses the function of efflux pump and down-regulates the resistance-associated genes through blocking the Pdr1-KIX interaction (Ki: 11.7 μM). Antifungal agent 72 is active against Fluconazole (HY-B0101)-resistant with a MIC value of 63 ng/mL, and shows synergistic inhibitory activity with Fluconazole. Antifungal agent 72 can be used for C. glabrata infection research .
    Antifungal agent 72
  • HY-138074
    Milbemycin A4 oxime

    5-Ketomilbemycin A4 oxime; 5-Oxomilbemycin A4 5-oxime

    		 Parasite Infection
    Milbemycin A4 oxime (5-Ketomilbemycin A4 oxime; 5-Oxomilbemycin A4 5-oxime) is a derivative of Milbemycin A4 (HY-126906) and a component of Milbemycin oxime (HY-B0778), both of which have insecticidal and nematicidal activities. Milbemycin A4 oxime (0.05 mg/kg) reduces the number of microfilariae in naturally infected dogs with D. immitis and inhibits the growth of clinical isolates of Candida glabrata (MIC80=16-32 μg/mL). Milbemycin A4 oxime (2.5 μg/mL) blocks the efflux of Fluconazole (HY-B0101) from clinical isolates of Candida glabrata. Milbemycin A4 oxime enhances doxorubicin-induced cell growth inhibition and increases the intracellular accumulation of doxorubicin and P-glycoprotein substrate Rhodamine 123 (HY-D0816) in doxorubicin-resistant but not sensitive MCF-7 breast cancer cells in a concentration-dependent manner.
    Milbemycin A4 oxime
  • HY-136757
    CYP51-IN-7

    		Fungal Infection
    CYP51-IN-2 (compound 1g), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-7
  • HY-136756
    CYP51-IN-6

    		Fungal Infection
    CYP51-IN-2 (compound 1f), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 15.6 ng/mL for Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-6
  • HY-136752
    CYP51-IN-2

    		Fungal Infection
    CYP51-IN-2 (compound 1b), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows 64 and 128 times higher activity than that of Fluconazole against Microsporum gypseum and Candida albicans, respectively .
    CYP51-IN-2
  • HY-119726B
    Fosmanogepix TFA

    		Fungal Infection
    Fosmanogepix TFA (APX001 TFA) is an orally active APX001A (HY-18233) prodrug and antifungal agent. Fosmanogepix TFA is effective against Cryptococcus neoformans, Fluconazole (HY-B0101)-resistant C. auris. Fosmanogepix TFA is effective in the treatment of invasive pulmonary aspergillosis and pulmonary murine mucormycosis .
    Fosmanogepix TFA
  • HY-186076
    Hsp90-IN-47

    		HSP Fungal Infection Cancer
    Hsp90-IN-47 (Compound C15) is a Hsp90 inhibitor and antifungal agent, with an IC50 of 0.014 μM against Hsp90α. When combined with Fluconazole (HY-B0101), Hsp90-IN-47 exerts significant synergistic antifungal effects against fluconazole-resistant Candida albicans 0304103. Hsp90-IN-47 exhibits antitumor activity against acute myeloid leukemia and non-small cell lung cancer .
    Hsp90-IN-47
  • HY-181404
    PA36-2

    		Fungal P-glycoprotein Infection
    PA36-2 is an Mdr1 inhibitor and azole resistance reversal agent, with a IC50 of 1.0 μg/mL and a Kd of 4.209 μM against Candida albicans Mdr1. By effectively inhibiting the activity of the Mdr1 efflux pump, PA36-2 prevents the pumping of substrates out of cells, enhances the intracellular accumulation of azole antibiotics, and exerts a synergistic effect with antifungal agents such as Fluconazole (FLC) (HY-B0101). PA36-2 can be used in the research of azole-resistant candidiasis .
    PA36-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: